0001140361-23-044839.txt : 20230921
0001140361-23-044839.hdr.sgml : 20230921
20230921212357
ACCESSION NUMBER: 0001140361-23-044839
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230719
FILED AS OF DATE: 20230921
DATE AS OF CHANGE: 20230921
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Helsel Dave
CENTRAL INDEX KEY: 0001543753
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50761
FILM NUMBER: 231270116
MAIL ADDRESS:
STREET 1: 400 WOOD ROAD
CITY: BRAINTREE
STATE: MA
ZIP: 02184
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ANGIODYNAMICS INC
CENTRAL INDEX KEY: 0001275187
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 113146460
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0531
BUSINESS ADDRESS:
STREET 1: 14 PLAZA DRIVE
CITY: LATHAM
STATE: NY
ZIP: 12110
BUSINESS PHONE: 5187981215
MAIL ADDRESS:
STREET 1: 14 PLAZA DRIVE
CITY: LATHAM
STATE: NY
ZIP: 12110
4/A
1
form4.xml
X0508
4/A
2023-07-19
2023-07-26
0001275187
ANGIODYNAMICS INC
ANGO
0001543753
Helsel Dave
14 PLAZA DRIVE
LATHAM
NY
12110
true
SVP Global Operations and R&D
false
Common Stock
2023-07-19
4
M
0
9650
0
A
37939
D
Common Stock
2023-07-19
4
F
0
3477
8.92
D
34462
D
Performance Right
2023-07-19
4
M
0
15081
0
D
Common Stock
15081
0
D
This acquisition of 9,650 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 14, 2020.
The exempt disposition of 3,477 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 14, 2020.
On July 14, 2020, the reporting person received a target grant of 15,081 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 9,650 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.
This Form 4/A is being filed to correct the number of shares received by the Reporting Person and subsequently sold to satisfy tax withholding obligations in connection with the vesting and settlement of performance share units on 07/19/2023 and provides corrected amounts in Columns 4 and 5 of Table I.
/s/ Stephen A. Trowbridge, Attorney in Fact
2023-09-21